TABLE OF CONTENTS
1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
1.3 OVERVIEW OF GLOBAL HEPARIN MARKET 38
1.4 CURRENCY AND PRICING 39
1.5 LIMITATIONS 40
1.6 MARKETS COVERED 40
2 MARKET SEGMENTATION 43
2.1 MARKETS COVERED 43
2.2 GLOBAL HEPARIN MARKET: GEOGRAPHICAL SCOPE 44
2.3 YEARS CONSIDERED FOR THE STUDY 45
2.4 CURRENCY AND PRICING 45
2.5 DBMR TRIPOD DATA VALIDATION MODEL 46
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.7 DBMR MARKET POSITION GRID 51
2.8 MARKET APPLICATION COVERAGE GRID 52
2.9 DBMR VENDOR SHARE ANALYSIS 53
2.10 MULTIVARIATE MODELING 54
2.11 PRODUCTS LIFELINE CURVE 54
2.12 SECONDARY SOURCES 55
2.13 ASSUMPTIONS 55
3 MARKET OVERVIEW 56
4 EXECUTIVE SUMMARY 57
5 PREMIUM INSIGHTS 62
6 REGULATORY PROCEDURE 64
7 GLOBAL HEPARIN MARKET, BY PRODUCT TYPE 67
7.1 OVERVIEW 68
7.2 UNFRACTIONATED HEPARIN 69
7.3 LOW MOLECULAR WEIGHT HEPARIN 70
7.3.1 ENOXAPARIN 71
7.3.2 DALTEPARIN 71
7.3.3 TINZAPARIN 71
7.3.4 FRAXIPARINE 71
7.3.5 OTHERS 71
7.4 ULTRA-LOW MOLECULAR WEIGHT HEPARIN 71
7.4.1 SEMULOPARIN 72
7.4.2 BEMIPARIN 72
7.4.3 OTHERS 72
8 GLOBAL HEPARIN MARKET, BY MODE OF ADMINISTRATION 73
8.1 OVERVIEW 74
8.2 ORAL 75
8.3 PARENTERAL ADMINISTRATION 75
8.3.1 SUBCUTANEOUS 76
8.3.2 INTRAVENOUS 76
8.3.3 INTRAPERITONEAL 76
8.3.4 OTHERS 76
9 GLOBAL HEPARIN MARKET, BY SOURCE 77
9.1 OVERVIEW 78
9.2 BOVINE 79
9.3 PORCINE 80
10 GLOBAL HEPARIN MARKET, BY INGREDIENTS 81
10.1 OVERVIEW 82
10.2 SODIUM 83
10.3 CALCIUM 84
10.4 OTHERS 85
11 GLOBAL HEPARIN MARKET, BY AVAILABILITY 86
11.1 OVERVIEW 87
11.2 RAW 88
11.3 PROCESSED 89
12 GLOBAL HEPARIN MARKET, BY TREATMENT 90
12.1 OVERVIEW 91
12.2 DEEP VEIN THROMBOSIS (DVT) 92
12.3 PULMONARY EMBOLISM (PE) 93
12.4 ARTERIAL THROMBOEMBOLISM (AT) 94
12.5 OTHERS 95
?
13 GLOBAL HEPARIN MARKET, BY APPLICATION 96
13.1 OVERVIEW 97
13.2 PRE-SURGICAL PROCEDURES 98
13.3 POST-SURGICAL PROCEDURES 99
13.4 KIDNEY DIALYSIS 100
13.5 DIAGNOSTIC TESTS 101
13.6 OTHERS 102
14 GLOBAL HEPARIN MARKET, BY THERAPEUTICS 103
14.1 OVERVIEW 104
14.2 CARDIOVASCULAR 105
14.3 RESPIRATORY 106
14.4 ONCOLOGY 107
14.5 NEPHROLOGY 108
14.6 CNS 109
14.7 OTHERS 110
15 GLOBAL HEPARIN MARKET, BY STRENGTH 111
15.1 OVERVIEW 112
15.2 10 UNITS 113
15.3 100 UNITS 114
15.4 1000 UNITS 115
15.5 5000 UNITS 116
15.6 10,000 UNITS 116
15.7 25,000 UNITS 117
15.8 OTHERS 117
16 GLOBAL HEPARIN MARKET, BY TYPE 118
16.1 OVERVIEW 119
16.2 GENERICS 120
16.3 BRANDED 121
16.3.1 LIPO-HEPIN 122
16.3.2 LIQUAEMIN 122
16.3.3 PANHEPARIN 122
16.3.4 HEP-LOCK 122
16.3.5 HEPALEAN (CALCIPARINE) 122
16.3.6 OTHERS 122
?
17 GLOBAL HEPARIN MARKET, BY CONTAINER 123
17.1 OVERVIEW 124
17.2 BOTTLES 125
17.3 BAGS 126
17.4 VIALS 127
17.5 OTHERS 127
18 GLOBAL HEPARIN MARKET, BY PACKAGING 128
18.1 OVERVIEW 129
18.2 GLASS 130
18.3 PLASTIC 131
19 GLOBAL HEPARIN MARKET, BY END USER 132
19.1 OVERVIEW 133
19.2 HOSPITALS 134
19.3 CLINICS 135
19.4 HOMECARE 136
19.5 AMBULATORY SURGICAL CENTERS 137
19.6 OTHERS 138
20 GLOBAL HEPARIN MARKET, BY DISTRIBUTION CHANNEL 139
20.1 OVERVIEW 140
20.2 HOSPITAL PHARMACY 141
20.3 RETAIL PHARMACY & DRUG STORE 142
20.4 ONLINE 143
20.5 OTHERS 144
21 HEPARIN MARKET, BY GEOGRAPHY 145
21.1 GLOBAL 146
21.2 NORTH AMERICA 151
21.2.1 U.S. 159
21.2.2 CANADA 165
21.2.3 MEXICO 170
21.3 EUROPE 175
21.3.1 GERMANY 184
21.3.2 U.K. 189
21.3.3 FRANCE 194
21.3.4 SPAIN 199
21.3.5 ITALY 204
21.3.6 RUSSIA 209
21.3.7 SWITZERLAND 214
21.3.8 NETHERLANDS 219
21.3.9 TURKEY 225
21.3.10 BELGIUM 230
21.3.11 REST OF EUROPE 235
21.4 ASIA-PACIFIC 236
21.4.1 JAPAN 245
21.4.2 CHINA 250
21.4.3 SOUTH KOREA 256
21.4.4 INDIA 261
21.4.5 AUSTRALIA 266
21.4.6 SINGAPORE 271
21.4.7 PHILIPPINES 276
21.4.8 INDONESIA 282
21.4.9 THAILAND 287
21.4.10 MALAYSIA 292
21.4.11 REST OF APAC 297
21.5 SOUTH AMERICA 298
21.5.1 BRAZIL 306
21.5.2 REST OF SOUTH AMERICA 311
21.6 MIDDLE EAST & AFRICA 312
21.6.1 SOUTH AFRICA 320
21.6.2 REST OF MIDDLE EAST & AFRICA 325
22 GLOBAL HEPARIN MARKET, COMPANY LANDSCAPE 326
22.1 COMPANY SHARE ANALYSIS: GLOBAL 326
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 327
22.3 COMPANY SHARE ANALYSIS: EUROPE 328
22.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 329
23 COMPANY PROFILES 330
23.1 SANOFI 330
23.1.1 COMPANY SNAPSHOT 330
23.1.2 REVENUE ANALYSIS 330
23.1.3 GEOGRAPHIC PRESENCE 331
23.1.4 PRODUCT PORTFOLIO 331
23.1.5 RECENT DEVELOPMENT 332
?
23.2 PFIZER INC. 333
23.2.1 COMPANY SNAPSHOT 333
23.2.2 REVENUE ANALYSIS 333
23.2.3 GEOGRAPHICAL PRESENCE 334
23.2.4 PRODUCT PORTFOLIO 334
23.2.5 RECENT DEVELOPMENT 336
23.3 FRESENIUS KABI AG 337
23.3.1 COMPANY SNAPSHOT 337
23.3.2 REVENUE ANALYSIS 337
23.3.3 GEOGRAPHICAL PRESENCE 338
23.3.4 PRODUCT PORTFOLIO 338
23.3.5 RECENT DEVELOPMENTS 339
23.4 F. HOFFMANN-LA ROCHE LTD 340
23.4.1 COMPANY SNAPSHOT 340
23.4.2 REVENUE ANALYSIS 340
23.4.3 GEOGRAPHICAL PRESENCE 341
23.4.4 PRODUCT PORTFOLIO 341
23.4.5 RECENT DEVELOPMENTS 341
23.5 MYLAN N.V. 342
23.5.1 COMPANY SNAPSHOT 342
23.5.2 REVENUE ANALYSIS 342
23.5.3 GEOGRAPHIC PRESENCE 343
23.5.4 PRODUCT PORTFOLIO 343
23.5.5 RECENT DEVELOPMENT 344
23.6 ASPEN HOLDINGS 345
23.6.1 COMPANY SNAPSHOT 345
23.6.2 REVENUE ANALYSIS 345
23.6.3 GEOGRAPHICAL PRESENCE 346
23.6.4 PRODUCT PORTFOLIO 346
23.6.5 RECENT DEVELOPMENTS 347
23.7 CHANGZHAOU QIANHONG BIO-PHARMA CO., LTD. 348
23.7.1 COMPANY SNAPSHOT 348
23.7.2 PRODUCT PORTFOLIO 348
23.7.3 RECENT DEVELOPMENT 349
23.8 EISAI CO., LTD. 350
23.8.1 COMPANY SNAPSHOT 350
23.8.2 REVENUE ANALYSIS 350
23.8.3 GEOGRAPHICAL PRESENCE 351
23.8.4 PRODUCT PORTFOLIO 351
23.8.5 RECENT DEVELOPMENT 351
23.9 HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO. LTD. 352
23.9.1 COMPANY SNAPSHOT 352
23.9.2 PRODUCT PORTFOLIO 352
23.9.3 RECENT DEVELOPMENTS 354
23.10 HIKMA PHARMACEUTICALS PLC 355
23.10.1 COMPANY SNAPSHOT 355
23.10.2 REVENUE ANALYSIS 355
23.10.3 GEOGRAPHIC PRESENCE 356
23.10.4 PRODUCT PORTFOLIO 356
23.10.5 RECENT DEVELOPMENT 357
23.11 LEO PHARMA A/S 358
23.11.1 COMPANY SNAPSHOT 358
23.11.2 REVENUE ANALYSIS 358
23.11.3 GEOGRAPHICAL PRESENCE 359
23.11.4 PRODUCT PORTFOLIO 359
23.11.5 RECENT DEVELOPMENT 360
23.12 NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD. 361
23.12.1 COMPANY SNAPSHOT 361
23.12.2 PRODUCT PORTFOLIO 361
23.12.3 RECENT DEVELOPMENTS 362
23.13 NOVARTIS AG 363
23.13.1 COMPANY SNAPSHOT 363
23.13.2 REVENUE ANALYSIS 363
23.13.3 GEOGRAPHICAL PRESENCE 364
23.13.4 PRODUCT PORTFOLIO 364
23.13.5 RECENT DEVELOPMENTS 364
23.14 OPOCRIN S.P.A. 365
23.14.1 COMPANY SNAPSHOT 365
23.14.2 PRODUCT PORTFOLIO 365
23.14.3 RECENT DEVELOPMENT 365
23.15 SARIA SE & CO. KG 366
23.15.1 COMPANY SNAPSHOT 366
23.15.2 PRODUCT PORTFOLIO 366
23.15.3 RECENT DEVELOPMENT 367
23.16 SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., LTD. 368
23.16.1 COMPANY SNAPSHOT 368
23.16.2 REVENUE ANALYSIS 368
23.16.3 GEOGRAPHICAL PRESENCE 369
23.16.4 PRODUCT PORTFOLIO 369
23.16.5 RECENT DEVELOPMENT 370
23.17 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 371
23.17.1 COMPANY SNAPSHOT 371
23.17.2 PRODUCT PORTFOLIO 371
23.17.3 RECENT DEVELOPMENT 371
23.18 SHENZHEN TECHDOW PHARMACEUTICAL CO., LTD 372
23.18.1 COMPANY SNAPSHOT 372
23.18.2 GEOGRAPHICAL PRESENCE 372
23.18.3 PRODUCT PORTFOLIO 373
23.18.4 RECENT DEVELOPMENTS 375
23.19 TEVA PHARMACEUTICAL INDUSTRIES LTD 376
23.19.1 COMPANY SNAPSHOT 376
23.19.2 REVENUE ANALYSIS 376
23.19.3 GEOGRAPHICAL PRESENCE 377
23.19.4 PRODUCT PORTFOLIO 377
23.19.5 RECENT DEVELOPMENT 377
23.20 YINO PHARMA LIMITED 378
23.20.1 COMPANY SNAPSHOT 378
23.20.2 PRODUCT PORTFOLIO 378
23.20.3 RECENT DEVELOPMENTS 378
24 QUESTIONNAIRE 379
25 CONCLUSION 385
26 RELATED REPORTS 386